论文部分内容阅读
Ames测验是遗传毒理实验(致畸致癌致突变)的初筛方法,是食品药品安全性检验中心的必检项目之一。结合部分中药体外致突变性(Ames检测)结果的混乱情况,提出修订现行Ames检测体系的必要性和紧迫性。通过对生物类样品中因含有组氨酸成分对Ames测验结果的影响作用(易产生假阳性)进行深入分析,并对目前国际上相关的Ames检测的修订方法进行综述和比较,指出了目前国内外尚没有适合中药致突变性检验的修订体系。在此基础上,提出了几条修订常规的Ames测验以适合中药体外致突变性检验的思路,以期引起应有的重视。
The Ames test is a preliminary screening method for genetic toxicology experiments (mutagenic mutagenesis) and is one of the mandatory items for the Food and Drug Safety Inspection Center. Combined with the chaotic situation of the in vitro mutagenicity (Ames test) results of some Chinese medicines, the necessity and urgency of revising the current Ames detection system were proposed. Through in-depth analysis of the effect of histidine in the biological samples on the results of Ames test (easy to produce false positives), the review and comparison of the current internationally relevant revision methods of Ames test, and pointed out the current domestic There is not yet a revised system for mutagenicity testing of Chinese medicines. On this basis, several amendments to the conventional Ames test were proposed to suit the in vitro mutagenicity test of Chinese herbal medicines in order to attract due attention.